🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 92536C103 (prev. 314462102 )
- Market Cap
- Small Cap
- Previous Symbol
- FHCO (changed 7/31/2017)
- Previous Name
- Female Health Co. (The)
Business: Veru Inc. is an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. The Veru prostate cancer pipeline includes VERU-111, zuclomiphene citrate, and VERU-100. VERU-111 is an oral, next-generation, first-in-class selective small molecule that targets and disrupts alpha and beta tubulin subunits of microtubules in cells to treat metastatic prostate cancer patients whose disease is resistant to both castration and novel androgen blocking agents (abiraterone or enzalutamide).
Company Contact
- CEO
- Mitchell S. Steiner
- CFO
- Michele Greco
- Headquarters
- 2916 N. Miami Avenue, Suite 1000, Miami, FL 33127
- Phone
- 305-509-6897
- Investor Relations
- Sam Fisch · 800-972-0538 · veruinvestor@verupharma.com